Twitter | Search | |
Search Refresh
LymphomaAction Jul 20
Promising developments for acalabrutinib in people with relapsed / refractory announced interim results from phase 3 ASCEND trial last month
Reply Retweet Like
Bichoy Gabra, R.Ph., Ph.D. 6h
On July 23, 2019, the approved (rituximab-pvvr), a to (rituximab) for the treatment of adult patients with CD20-positive B-Cell and CD20-positive . Ruxience Prescribing Information
Reply Retweet Like
WheelieDealer Jul 18
Confident update from - "at least in line with expectations" - quality business and over 3% divvy - I'm a prize pillock for selling these a while back.
Reply Retweet Like
The Lancet Haematology Jul 17
NEW research—obinutuzumab & ibrutinib induction therapy followed by a MRD-driven treatment strategy is safe and active as first line therapy in patients with : results from the ICLL07 FILO trial
Reply Retweet Like
cnag-crg Jul 22
📢 We have openings for two PhD students through the EU-funded Synergy project BCLLatlas, on multi-omic single-cell characterisation of B-cells for chronic lymphocytic leukaemia () ⏳Apply by July 31st ➡️
Reply Retweet Like
DIVAOnline Jul 17
In French, you don’t really say “I miss you”, you say “Tu me manques” which means “You are missing from me.”
Reply Retweet Like
CLL Society Inc. Jul 22
Don't let a cancer diagnosis lead to financial ruin. Check out our webinar on how to avoid financial toxicity.
Reply Retweet Like
Patient Empowerment Jul 22
A panel of Chronic Lymphocytic Leukemia (CLL) patients and their family discuss relationships and navigating together.
Reply Retweet Like
Michele Nadeem-Baker 23h
Patients still need to be diligent about all other medical screenings. Mammograms are still necessary! Great experience at MGH
Reply Retweet Like
Brian Barrett 21h
Sometimes you need to look at familiar things from a different angle and it changes everything
Reply Retweet Like
Anthony Norris Jul 20
Reply Retweet Like
Amanda Marie Jul 15
Thankfully I’m insured but this medication is treating my which is a form of leukemia found in those over 65 years old (I’m an anomaly). Last I checked, it is not covered under Medicare.
Reply Retweet Like
Phoebe Needles Jul 19
Check out our August 13th program here:
Reply Retweet Like
Joe Jul 16
is now officially have 2 drugs in humans! APTO-253 1st 2 patients passed the 28 days cycle of treatment & started Cohort-3 with 66mg/m2 dose CG-806 dosed 1st patient 150mg every 12 hours which in preclinical showed activity More info in 2-3 weeks at Q2 earnings call
Reply Retweet Like
CellworksLife Jul 16
Data from recent studies continue to demonstrate the potency and tolerability of BTK inhibitors as and in combination for the treatment of patients with chronic lymphocytic leukemia both in the frontline and relapsed/refractory settings.
Reply Retweet Like
Prof John Jul 22
🏡🏪🏥🏘️🏢 LOCATION, LOCATION, LOCATION... V NICE REVIEW from Susan Pierce & Colleagues on 'B-Cell Signalling In Context'
Reply Retweet Like
Joe Jul 16
Very important milestone. So now 's CG-806 "In Clinic" & dosed 1st patient & need 28 days cycle to evaluate & then dose 2nd patient. With 7 centers enrolling, I can assume 2nd patient will be dosed soon after 1st patient DSMB evaluation. Things start rolling
Reply Retweet Like
Sigrid Skånland Jul 22
Looking forward to presenting our poster “An in vitro assay for discovery and dose prediction applied to plus treatment of ” at ! Edinburgh, 20-23 September.
Reply Retweet Like
Cowan, Liebowitz Jul 19
On My Mind Blog - Is a Licensee Permitted to Challenge a Licensor’s IP Rights?
Reply Retweet Like
Raul Cordoba, MD, PhD 22h
IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia | ⁦
Reply Retweet Like